{"DataElement":{"publicId":"7717421","version":"2","preferredName":"Systemic Therapy Administered Name","preferredDefinition":"A description of the systemic therapy that was administered.","longName":"chemo_receipt","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2014193","version":"1","preferredName":"Systemic Therapy Administered","preferredDefinition":"the administration of systemic therapy to an individual.","longName":"SYSTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176918","version":"1","preferredName":"Systemic Therapy","preferredDefinition":"(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"Systemic Therapy","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AF4-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5ECCD8F-CB00-09C1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-05","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-02-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7717416","version":"2","preferredName":"Systemic Therapy Name","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._The words or language units by which a thing is known.","longName":"SYSTEM_THER_NAME","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other Experimental/Clinical Trial","valueDescription":"Other Investigational Therapeutic Procedure Or Therapeutic Clinical Trial","ValueMeaning":{"publicId":"7717417","version":"1","preferredName":"Other Investigational Therapeutic Procedure Or Therapeutic Clinical Trial","longName":"7717417","preferredDefinition":"Different than the one(s) previously specified or mentioned.: In the process of being studied; experimental.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A clinical study that involves administering of exposure to the agent/agents to subjects with particular disease to elucidate the most appropriate treatment for a specific medical condition, or to prolong or improve the patient's life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Investigational","conceptCode":"C28041","definition":"In the process of being studied; experimental.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Clinical Trial","conceptCode":"C39536","definition":"A clinical study that involves administering of exposure to the agent/agents to subjects with particular disease to elucidate the most appropriate treatment for a specific medical condition, or to prolong or improve the patient's life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C688350B-A03D-5126-E053-4EBD850A7353","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"ONEDATA","dateModified":"2021-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-72F2-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-72FC-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7306-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Biologic therapy","valueDescription":"Biological Therapy","ValueMeaning":{"publicId":"3198847","version":"1","preferredName":"Biological Therapy","longName":"3198847","preferredDefinition":"Biological therapy is a form of treatment that implies the administration of substances which produce a biological reaction in the organism enhancing or restoring the host immune response, modifying the behavior of cancer cells, blocking the pathways of cell neoplastic transformation and tumor ability to metastasize, or facilitating the repairment of cells damaged by aggressive forms of cancer treatment.  It includes the use of sera, antitoxins, vaccines, genes, cells, tissues, and organs","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biological Therapy","conceptCode":"C15187","definition":"A type of treatment that uses substances derived from or made by living organisms to treat disease; this includes both naturally occurring and synthetic products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D999C94-A599-E80A-E040-BB89AD4330DB","latestVersionIndicator":"Yes","beginDate":"2011-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7310-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Immuno-therapy","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"5102332","version":"1","preferredName":"Immunotherapy","longName":"5102332","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-01FA-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-731A-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7324-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Bevacizumab/Avastin","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-732E-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Vincristine Sulfate","valueDescription":"Vincristine Sulfate","ValueMeaning":{"publicId":"6159977","version":"1","preferredName":"Vincristine Sulfate","longName":"6159977","preferredDefinition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine Sulfate","conceptCode":"C1739","definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4CB5-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7338-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Procarbazine Hydrochloride","valueDescription":"Procarbazine Hydrochloride","ValueMeaning":{"publicId":"6159914","version":"1","preferredName":"Procarbazine Hydrochloride","longName":"6159914","preferredDefinition":"The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine Hydrochloride","conceptCode":"C773","definition":"The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5C17-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7342-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Lomustine/Gleostine","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-734C-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"PCV regimen","valueDescription":"PCV Regimen","ValueMeaning":{"publicId":"7717419","version":"1","preferredName":"PCV Regimen","longName":"7717419","preferredDefinition":"A regimen consisting of procarbazine, lomustine and vincristine used for the treatment of gliomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PCV Regimen","conceptCode":"C63491","definition":"A regimen consisting of procarbazine, lomustine and vincristine that may be used for the treatment of certain central nervous system (CNS) cancers including glioma, oligodendroglioma and astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C688350B-A0EF-5126-E053-4EBD850A7353","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"ONEDATA","dateModified":"2021-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7356-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"No systemic therapy received","valueDescription":"Negation Systemic Therapy","ValueMeaning":{"publicId":"7717420","version":"1","preferredName":"Negation Systemic Therapy","longName":"7717420","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C688350B-A112-5126-E053-4EBD850A7353","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"ONEDATA","dateModified":"2021-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-7360-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Temozolomide/Temodar/TMZ","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-736A-61B8-E053-4EBD850A1221","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Cisplatin/Carboplatin + Pemetrexed","valueDescription":"Carboplatin Cisplatin And Pemetrexed","ValueMeaning":{"publicId":"8070668","version":"1","preferredName":"Carboplatin Cisplatin And Pemetrexed","longName":"8070668","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D967C9A6-7386-61B8-E053-4EBD850A1221","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-73A1-61B8-E053-4EBD850A1221","beginDate":"2022-03-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Ipilimumab/Nivolumab","valueDescription":"Ipilimumab and Nivolumab Regimen","ValueMeaning":{"publicId":"6409150","version":"1","preferredName":"Ipilimumab and Nivolumab Regimen","longName":"6409150","preferredDefinition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of kidney cancer and melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab/Nivolumab Regimen","conceptCode":"C154272","definition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone cancer, kidney cancer, colorectal cancer, melanoma, non-small cell lung cancer (NSCLC), and malignant pleural/peritoneal mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-661C-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"SOKKERL","dateModified":"2019-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-73B9-61B8-E053-4EBD850A1221","beginDate":"2022-03-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Cisplatin/Carboplatin + Pemetrexed + anti-PD-1/L1 agents","valueDescription":"Cisplatin/Carboplatin + Pemetrexed + anti-PD-1/L1 agents","ValueMeaning":{"publicId":"8070669","version":"1","preferredName":"Cisplatin/Carboplatin + Pemetrexed + anti-PD-1/L1 agents","longName":"8070669","preferredDefinition":"Cisplatin/Carboplatin + Pemetrexed + anti-PD-1/L1 agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D967C9A6-73C3-61B8-E053-4EBD850A1221","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D967C9A6-73DC-61B8-E053-4EBD850A1221","beginDate":"2022-03-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7717415","version":"1","preferredName":"Systemic Therapy Name","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.:The words or language units by which a thing is known.","longName":"C15698:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C688350B-A00E-5126-E053-4EBD850A7353","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"ONEDATA","dateModified":"2021-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCG:Center for Cancer Genomics","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D967C9A6-72DA-61B8-E053-4EBD850A1221","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"MAESKEB","dateModified":"2022-03-04","changeDescription":"2021-7-7- ak Created for CCG HOPE-CARE.; 2022-03-04 versioned to increase max length and to add PVs bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6705584","version":"1","longName":"CCG PTCL (Center for Cancer Genomics - Peripheral T Cell Lymphoma)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"7715738","version":"1","longName":"HOPE-CARE","context":"NCIP"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Which systemic therapy receiv","type":"Preferred Question Text","description":"Which systemic therapy received?","url":null,"context":"NCIP"},{"name":"NRG_CRF_Text1","type":"Alternate Question Text","description":"Pre-study neoadjuvant systemic therapy regimen.","url":null,"context":"NRG"}],"origin":"CCG:Center for Cancer Genomics","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D967DB04-B693-61BC-E053-4EBD850A2703","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-04","modifiedBy":"BAUSINGT","dateModified":"2022-03-07","changeDescription":"2021-7-7 ak Created for CCG HOPE-CARE.; 2022-03-04 versioned CDE to increase max length and addition of PVs bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}